4//SEC Filing
Urist Marshall 4
Accession 0001802768-25-000101
CIK 0001802768other
Filed
Aug 7, 8:00 PM ET
Accepted
Aug 8, 4:52 PM ET
Size
9.5 KB
Accession
0001802768-25-000101
Insider Transaction Report
Form 4
Urist Marshall
EVP, Research & Investments
Transactions
- Award
Class A Ordinary Shares
2025-08-06+2,772→ 39,256 total - Gift
LP interests in RPI US Partners 2019, LP
2025-08-08−3,000→ 263,412 total(indirect: By LLC)→ Class A Ordinary Shares (30,000 underlying)
Holdings
- 46,667(indirect: By LLC)
Class A Ordinary Shares
- 19,020(indirect: By IRA)
Class A Ordinary Shares
Footnotes (3)
- [F1]Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
- [F2]No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
- [F3]Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001838139
Filing Metadata
- Form type
- 4
- Filed
- Aug 7, 8:00 PM ET
- Accepted
- Aug 8, 4:52 PM ET
- Size
- 9.5 KB